Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 Plus Chemotherapy in Resectable Gastric/GEJ Cancer
NCT05149807Phase 3Terminated
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Jan 2022
- Primary completion
- Apr 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of retlirafusp alfa in gastric cancer (GC), gastroesophageal junction cancer, sponsored by Suzhou Suncadia Biopharmaceutical. Started Jan 2022; status: terminated.
02
Drugs
retlirafusp alfa
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT05149807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05149807.